U.S., May 15 -- ClinicalTrials.gov registry received information related to the study (NCT06971614) titled 'A Study of T3011 in Patients With BCG-Unresponsive High Risk NMIBC' on April 27.
Brief Summary: This is a single-arm, open-label, multicenter, phase II clinical study to evaluate the tolerability, safety, and preliminary efficacy of intravesical administration of Herpes Virus T3011 Injection in participants with BCG-unresponsive high risk non-muscle-invasive bladder cancer (NMIBC) .
Study Start Date: May 30
Study Type: INTERVENTIONAL
Condition:
Nonmuscle-invasive Bladder Cancer
Intervention:
BIOLOGICAL: T3011
In the dose expansion period, 2x10^9 PFU dose level will be supposed as the 1st expansion dose . 1x10^10 PFU dose level...